Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ICACT: Second-Line Paclitaxel and Carboplatin Show Promising Results in Advanced Gastric Cancer By Chris Berrie PARIS, FRANCE -- February 2, 2005 -- Second-/third-line chemotherapy that combines paclitaxel and carboplatin appears to be well tolerated, with promising response rates and rates of disease stabilisation in patients with advanced gastric cancer. Final results from a phase 2 trial were presented here on February 2nd at the 16th International Conference on Anti-Cancer Treatment. There are as yet no second/third-line chemotherapy treatments that have shown better than 25% to 35% response rates in gastric cancer; in particular, with respect to any specific gains in duration of response and survival benefit to the patient, stated George Samelis, MD, PhD, Deputy Head, Oncology Department, Hippokration General Hospital of Athens, Athens, Greece. "Advanced gastric cancer is a lethal disease and we do not have any real chemotherapy combinations that are able to improve the survival and quality of life of these patients," he said. Following up on a small series of phase 2 trials over the past 10 years or so, the potential of paclitaxel for gastric cancer has emerged, and therefore this study was designed to investigate its possibility as a 2nd/3rd-line chemotherapy approach when combined with carboplatin. The 22 patients enrolled (73% male; median age, 64 years; range, 43-79 years) had histologically confirmed gastric adenocarcinoma with a performance status of 0-1, and had previously had 5-fluorouracil-based chemotherapies. Furthermore, 41% and 9% had undergone previous operations and radiotherapy, respectively, and 50% had been deemed inoperable. Treatment consisted of 175 mg/m2 paclitaxel and carboplatin at an area under the curve of 5 on day 1, with repeat dosing every 3 weeks. With the total number of cycles administered at 103, the median number of cycles each patient received was 6 (range, 2-9). Complete and partial responses represented 4.5% and 9.0% of patients, respectively, and progressive disease was achieved in 41%. Stable disease, however, was obtained in 45% of patients. These data gave a median time to progression of 6 months (range, 2-29 months) and a median survival of 7.5 months (range, 3-30 months). Dr. Samelis stressed that this combination of paclitaxel and carboplatin not only gave a reasonable overall response rate of 13.5%, but more importantly, it represents the first example of second-line chemotherapy for advanced gastric cancer that can provide good stability and quality of life. He concluded that the next stage of research into this regimen will be to compare these very promising results in randomised phase 3 trials with other established second/third-line chemotherapy regimens to establish the real benefits that this paclitaxel and carboplatin combination is offering towards the quality of life and the survival of patients with advanced gastric cancer. [Study Title: Second-Line Chemotherapy With Paclitaxel and Carboplatin in Advanced Gastric Cancer (Final Results).] E-mail this page to a friend or colleague! To print, use this version